Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 2 Interventional

Safety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual Onychomycosis

ClinicalTrials.gov ID: NCT07929844

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07929844. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-Blind Study Evaluating the Safety and Efficacy of SKX-16 (Luliconazole 10% Solution) in Participants With Mild to Moderate Distal Subungual Onychomycosis of the Toenails

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a parallel group, double blind, vehicle-controlled study in which SKX-16 or vehicle (2:1 randomization) is applied once a day for 52 weeks to all affected toenails to participants with mild to moderate distal subungual onychomycosis (DSO) of the toenails involving between 20 to 50% of at least one great toenail at Screening.

Study identification

NCT ID
NCT07929844
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
SATO Pharmaceutical Co., Ltd.
Industry
Enrollment
204 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 24, 2026 (Estimated)
Primary completion
Sep 23, 2028 (Estimated)
Completion
Oct 21, 2028 (Estimated)
Last update posted
Nov 10, 2026

2026 – 2028

United States locations

U.S. sites
6
U.S. states
3
U.S. cities
5
Facility City State ZIP Site status
SKX16B01 Clinical Study - Site 105 Los Angeles California 900045 —
SKX16B01 Clinical Study - Site 101 San Francisco California 94115 —
SKX16B01 Clinical Study - Site 104 Miami Florida 11760 —
SKX16B01 Clinical Study - Site 109 Miami Florida 33126 —
SKX16B01 Clinical Study - Site 111 College Station Texas 77845 —
SKX16B01 Clinical Study - Site 119 Houston Texas 77027 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07929844, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 10, 2026 · Synced Nov 15, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.